NEW YORK (GenomeWeb) – Diagnostics firm OncoCyte said today that it has raised $5.74 million through the cash exercise of 1,766,923 common stock purchase warrants by certain warrant holders.

Oncocyte President and CEO William Annet said in a statement that the proceeds will help advance the development of the firm's novel liquid biopsy diagnostics for lung and breast cancer and prepare for the launch of its lung cancer diagnostic in the second half of 2017.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.